#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow